Showing 3331-3340 of 5525 results for "".
- Tralokinumab Data for H&N AD Presented at EADVhttps://practicaldermatology.com/news/tralokinumab-data-hn-ad-presented-eadv/2468323/Nine-month interim data from the TRACE study, showing that tralokinumab/tralokinumab-ldrm reduced the severity of moderate-to-severe atopic dermatitis (AD) in the head and neck region of the body (H&N), were shared through one of LEO Pharma’s five late-breaking oral presentations at the 33rd
- Eczema Patients at Higher Risk for Comorbidities, Study Findshttps://practicaldermatology.com/news/eczema-patients-higher-risk-comorbidities-study-finds/2468064/Recent analysis of data from the NIH’s All of Us Research Program reveals significant associations between atopic dermatitis (AD) and other health conditions, underscoring the multifaceted burdens faced by AD patients. The All of Us Research Program, which collected health data from over 8
- Analysis Shows High Incidence of Skin Eruptions with Tebentafusp in Uveal Melanomahttps://practicaldermatology.com/news/high-incidence-skin-eruptions-tebentafusp-uveal-melanoma/2468062/Tebentafusp-associated skin toxicity was prevalent in patients treated for metastatic uveal melanoma, a recent study reported. Study researchers looked at a cohort study of 33 patients treated with tebentafusp and identified skin symptoms in 26 patients (median follow-up of 21.5 months for
- Analysis: COX1 Genotype Determines Fish Oil’s Efficacy Against ADhttps://practicaldermatology.com/news/analysis-cox1-genotype-determines-fish-oils-efficacy-against-ad/2467997/A secondary analysis of a randomized clinical trial indicated prenatal ω-3 long-chain polyunsaturated fatty acid (n-3 LCPUFA) supplementation may reduce the risk of childhood atopic dermatitis (AD) in a genotype-specific manner. Researchers for the analysis reported that mothers carrying t
- Promotional vs. Educational: Skin Condition Posts on Instagram and TikTokhttps://practicaldermatology.com/news/promotional-vs-educational-skin-condition-posts-instagram-and-tiktok/2467249/New research revealed differences in the types of dermatology content present on the Instagram and TikTok social media platforms. Researchers publishing in the Journal of Drugs in Dermatology looked specifically at content on the Instagram and TikTok social media platforms relat
- Event Promotes Anti-Itch Cream for Stopping Pesky Bugs From Disrupting Summer Funhttps://practicaldermatology.com/news/event-promotes-anti-itch-cream-stopping-pesky-bugs-disrupting-summer-fun/2467168/Summer is in full swing and as patients spend more time outdoors, bug bites and other skin irritants will find a way to disrupt the fun.
- Study: Advanced AI Enhances Melanoma Detectionhttps://practicaldermatology.com/news/study-advanced-ai-enhances-melanoma-detection/2467071/A new study suggests a novel deep-learning model based on diagnostic data may help harness the power of neural networks and artificial intelligence (AI) to more accurately diagnose melanoma.
- Emerging Technologies, Consumer Preferences Drive Microdermabrasion Market Expansionhttps://practicaldermatology.com/news/emerging-technologies-and-consumer-preferences-drive-microdermabrasion-market-expansion/2466901/A new market report indicates that microdermabrasion devices are increasingly favored in the treatment of conditions like acne, acne scars, fine lines, and wrinkles, and that the market for these devices is poised for growth. The growth, according to the report from Coherent Market Insig
- J&J Expands Atopic Dermatitis Pipeline with Yellow Jersey Therapeutics Acquisitionhttps://practicaldermatology.com/news/jj-expands-ad-pipeline-yellow-jersey-therapeutics-125-billion-acquisition/2463207/Johnson & Johnson (J&J) has announced its plan to acquire Yellow Jersey Therapeutics (a subsidiary of Numab Therapeutics) for $1.25 billion in cash, according to a news release. The acquisition includes the bispecific antibody NM26, which is currently advancing to phase 2 studies f
- Boehringer Ingelheim Partners with Cigna's Quallent to Expand Access to Humira Biosimilarhttps://practicaldermatology.com/news/boehringer-ingelheim-partners-cignas-quallent-expand-access-humira-biosimilar/2463055/